Expression of the bcl-2 oncoprotein in meningiomas

American Journal of Clinical Pathology

Volumn 106, Issue 5, 1996, Pages 652-659

  Mosnier, Jean François ^a   Perret, Anne Gentil ^a   Brunon, Jacques ^a   Boucheron, Simonne ^a  

^a SERVICE DE NEUROLOGIE   (France)

Author keywords

bcl 2; Estrogen receptor; Meningioma; Neural cell adhesion molecule; Progesterone receptor

Indexed keywords

HORMONE RECEPTOR; NERVE CELL ADHESION MOLECULE; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GROWTH REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MENINGIOMA; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

EID: 0029827654     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/106.5.652     Document Type: Article

References (51)

1. Applanat MP, Groyer-Picard MTH, Kujas M. Immunocytochemical study of progesterone receptors in human meningiomas. Acta Neurochir 1992;115:20-30.
2. Maxwell M, Galapoulos T, Neville-Golden J, Antoniades HN. Expression of androgen and progesterone receptors in primary human meningiomas. J Neurosurg 1993;78:456-462.
3. Schoultz EV, Bixo M, Blackstrom T, Silfvenius H, Wilking N, Henrikson R. Sex steroids in human brain tumors and breast cancer. Cancer 1990;65:949-952.
4. Whittle IR, Foo MS, Besser M, Vanderfield GK. Progesterone and estrogen receptors in meningiomas: Biochemical and clinicopathological considerations. Austr NZ J Surg 1984;54:325-330.
5. Hockenberry DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88: 6961-6965.
6. Hockenberry D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336.
7. Korsmeyer SJ. bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 1992;80:879-886.
8. Vaux DL, Cory S, Adams JM. bcl-2 promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-442.
9. Mac Donnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 1991;349:254-256.
10. Bronner MP, Culin C, Reed JC, Furth EE. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 1995;146:20-26.
11. Hague A, Moorghen M, Hicks D, Chapman M, Paraskeva C. bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene 1994;9:3367-3370.
12. Lu L, Poulsom R, Wong L, Hanby AM. bcl-2 expression in adult and embryonic non haemopoietic tissues. J Pathol 1993;169: 431-437.
13. Reed JC, Meister L, Tanaka S, et al. Differential expression of bcl-2 protooncogene in neuroblastoma and other tumor cell lines of neural origin. Cancer Res 1991;51:6529-6538.
14. van den Oord JJ, Vandeghenate N, De Ley M, De Wolf-Peters C. bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994;45:294-300.
15. Burger PC, Vogel FS. Surgical Pathology of the Nervous System and Its Covering, ed 2. New York: John Wiley and Son, 1982, pp 226-242.
16. Russel DS, Rubinstein LJ. Pathology of the Tumors of the Nervous System. ed 5. London: Edward Arnold, 1989, pp 449-507.
17. Figarella-Branger D, Pelissier J-F, Bouillot P, et al. Expression of neural cell-adhesion molecule isoforms and epithelial cadherin adhesion molecules in 47 human meningiomas: Correlation with clinical and morphological data. Mod Pathol 1994;7:752-761.
18. Patel K, Frost G, Kiely F, Phimister E, Coakham HB, Kemshead JT. Expression of the cluster 1 antigen (neural cell adhesion molecule) in neuroectodermal tumours. Br J Med 1991;63 (suppl XIV):20-23.
19. Roggendorf W, Schuster T, Peiffer J. Proliferative potential of meningiomas determined with the monoclonal antibody Ki-67. Acta Neuropathol 1987;73:361-367.
20. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.
21. Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumors of the Central Nervous System. WHO International Histological Classification of Tumours. Berlin: Springer Verlag, 1993, pp 33-37.
22. Jääskelainen J, Haltia M, Laasonen E, Wahlström T, Valtonen S. The growth rate of intracranial meningiomas and its relation to histology: An analysis of 43 patients. Surg Neurol 1985;24:165-172.
23. Mason DY, Sammons RE. The labeled antigen method of immunoenzymatic staining. J Histochem Cytochem 1979;27:832-840.
24. Graham RC, Karnovsky MJ. The early stages of absorption of horseradish peroxidase in the proximal tubules of mouse kidney: Ultrastructural cytochemistry by a new technique. J Histochem Cytochem 1966;14:291-302.
25. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-46.
26. Reed J, Cuddy M, Haldar S, Croce C, Nowell P, Makover D. bcl-2-mediated tumorigenicity in a human T-lymphoid cell line: Synergy with c-myc and inhibition by bcl-2 antisense. Proc Natl Acad Sci USA 1990;87:3660-3663.
27. Buttyan R, Olsson CA, Pintar J, et al. Induction of the TRPM-2 gene in cells undergoing programmed death. Mol Cell Biol 1989;9:3473-3481.
28. Pezella F, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the t(14; 18) chromosomal translocation. Am J Pathol 1990;137:225-232.
29. Colombel M, Symmons F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Path 1993;143:390-400.
30. Ngan BY, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML. Expression in non Hodgkin lymphoma of the bcl-2 protein associated with the t(14; 18) translocation. N Engl J Med 1988;318: 1638-1644.
31. Doussis IA, Pezella F, Lane DP, Gatter KC, Mason DY. An immunohistochemical study of p53 and bcl-2 protein expression in Hodgkin's disease. Am J Clin Pathol 1993;99:663-667.
32. Lorenzen J, Hansmann M-L, Pezella F, et al. Expression of bcl-2 oncogene product and chromosomal translocation t(14 ; 18) in Hodgkin's disease. Hum Pathol 1992;23:1205-1209.
33. Alguacil-Garcia A, Pettigrew NM, Sima AAF. Secretory meningioma: A distinct subtype of meningioma. Am J Surg Pathol 1986;10:102-111.
34. Artlich A, Schmidt D. Immunohistochemical profile of meningiomas and their histological subtypes. Hum Pathol 1990;21:843-849.
35. Holden J, Dolman CL, Churg A. Immunohistochemistry of meningiomas including the angioblastic type. J Neuropathol Exp Neurol 1987;46:50-56.
36. Meis JM, Ordonez NG, Bruner JM. Meningiomas: An immunohistochemical study of 50 cases. Arch Pathol Lab Med 1986;110:934-937.
37. Theaker JM, Gatter KC, Esiri MM, Fleming KA. EMA and cytokeratin expression by meningiomas. An immunohistochemical study. J Clin Pathol 1986;39:435-439.
38. Kruse J, Mainhammer R, Wernecke H, et al. Neural cell adhesion molecules and myelin-associated glycoprotein share a common carbohydrate moiety recognized by monoclonal antibody L2 and HNK-1. Nature 1984;311:153-155.
39. Figarella-Branger DF, Durbec PL, Rougon GN. Differential spectrum of expression of Neural Cell Adhesion Molecule Isoforms and L1 Adhesion Molecules on human neuroectodermal tumors. Cancer Res 1990;50:6364-6370.
40. Miettinen M, Cupo W. Neural Cell Adhesion molecule distribution in soft tissue tumors. Hum Pathol 1993;24:62-66.
41. Yamashima T, Kida S, Yamamoto S. Ultrastructural comparison of arachnoid villi and meningioma in man. Mod Pathol 1988;1: 224-234.
42. Tohma Y, Yamashima T, Yamashita J. Immunohistochemical localization of cell adhesion molecule Epithelial Cadherin in human arachnoid villi and meningiomas. Cancer Res 1992;52: 1981-1987.
43. Lee KS, Hoshino T, Rodriguez LA, Bederson J, Davis RL, Wilson CB. Bromodeoxyuridine labeling study of intracranial meningiomas: Proliferative potential and recurrence. Acta Neuropathol 1990;80:311-317.
44. Zorludemir S, Scheithauer BW, Hirose T, Van Houten C, Miller G, Meyer FB. Clear cell meningioma: A clinicopathologic study of a potentially aggressive variant of meningioma. Am J Surg Pathol 1995;19:493-505.
45. Davis C. Meningiomas and sex hormones. Eur J Cancer 1990;26: 859-860.
46. Donnel MS, Meyer GA, Donegan WL. Estrogen receptor protein in intracranial meningiomas. J Neurosurg 1979;50:499-502.
47. Schrell UMH, Adams EF, Fahlbush R, et al. Hormonal dependency of cerebral meningiomas. Part I: Female sex hormone and their significance as specific markers for adjuvant medical therapy. J Neurosurg 1990;73:743-749.
48. Joensuu H, Pylkkanen L, Toikkanen S. bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994;145: 1191-1198.
49. Leek RD, Kaklamanis L, Pezella F, Gatter KC, Harris AL. bcl-2 in normal breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994;69:135-139.
50. Dogliani C, Del Tos B, Laurino L, Chiarolli C, Barbareschi M, Viale G. The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates with particular reference to oestrogen receptor status. Virchows Arch 1994;424: 47-51.
51. Gompel A, Sabourin JC, Martin A, et al. bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol 1994;144:1195-1202.